Multiorgan Dysfunction in Surgical Patients — Scores, Crosstalk, Support Sequencing and Survival

The multiply-injured patient who survives bleeding dies of failing organs — so define the failure with SOFA-2's six revised systems or Marshall's 24-point score or Denver's trauma-simple rule, watch the delta not the admission snapshot, treat the kidney-lung-gut-liver-brain conversation rather than any single organ, sequence support by the trials that moved organ endpoints, and follow every survivor: because postinjury MOF still strikes a quarter of polytrauma patients with no fall over time, early AKI predicts MOF better than early heart, lung or liver failure, hydrocortisone-plus-fludrocortisone is the only support drug that cut septic-shock death while bicarbonate, vitamin C and acetaminophen did not move MOD endpoints, and Swedish survivors still die at triple the rate two to twelve months on.^{[1][14][23][22][24][25][61]}

Day 2 after damage-control laparotomy for blunt polytrauma, a 54-year-old man is oliguric, hypoxic, jaundiced and confused with platelets falling. Is this MODS, which score names it and which trajectory predicts his death, is his kidney injuring his lung or the reverse, does his coagulopathy want SIC scoring or heparin, which of four support drugs changes his organ-failure-free days, and what do you tell his family about the year after discharge? The examiner will watch you score serially rather than once, quote the crosstalk papers behind each organ move, refuse unselected anticoagulation with numbers, and book PICS screening. This page teaches each move with every number taken from the paper named beside it.^{[33][34][10][20][23][67]}

Definitions & Scores — SOFA original to SOFA-2, Marshall, Denver

Organ dysfunction is graded, not merely counted: the 1996 SOFA original described six-system dysfunction for sepsis-related problems, and the 2025 SOFA-2 revision re-thresholded the same six systems — brain, respiratory, cardiovascular, liver, kidney, haemostasis — across 3.34 million encounters in 1319 ICUs, improving discrimination to AUROC 0.79 from 0.77 while admitting that gastrointestinal and immune dysfunction still lack the data and content validity for inclusion.^[30][26] The update was forced by practice itself: three decades of new interventions and non-invasive monitoring made the original thresholds unfit for modern care, which is exactly the debate Moreno's SOFA 2.0 proposal opened.^[31] Marshall's 1995 Multiple Organ Dysfunction Score remains the surgical workhorse — six systems summed to 24, ICU mortality 25% at 9-12 points, 50% at 13-16, 75% at 17-20 and 100% above 20, with development and validation AUCs of 0.936 and 0.928 — and its delta, the increment acquired during the ICU stay, carried more explanatory power than any admission severity index.^[33] After major trauma the three scores describe different diseases: Denver labelled 22.8%, Marshall 40.5% and SOFA 58.5% as MOF, Denver carried the strongest death signal (hazard ratio 3.87) with the highest specificity (81%) against SOFA's highest sensitivity (73%) — hence the recommendation that Denver, simplest to calculate, owns early trauma mortality prediction.^[2] The examined honesty clause comes from Braasch: on surgical days three and five, SOFA was fully calculable in only about a fifth of patients, MODS in about a twentieth, Denver in about a third of trauma patients — PaO2/FiO2, CVP and bilirubin missing most — so every published score hides imputation the candidate must declare.^[35]

Surgical & Trauma Epidemiology — who gets MOF, who dies

Postinjury MOF is the leading cause of late trauma death, yet its incidence is a property of its definition: 284 studies used 11 inclusion criteria and 40 MOF definitions, and across 351,942 patients 82,971 (24%) developed MOF, with weighted incidence swinging from 11% to 56% by publication year and no significant fall over time.^[1] In the surgical ICU specifically, MODS remains the most important mortality factor, with death tracking overall severity plus the number of systems involved — while the gut, liver and central nervous system still defeat adequate definition, which is why biological markers may eventually beat scores.^[5] The ruptured-AAA repair cohort makes trajectories examinable: 40% 30-day mortality with bimodal ICU death, flat daily MOD scores in survivors against progressively rising scores in late deaths, delta-MOD beating APACHE II, and renal plus hepatic components — not respiratory — separating late deaths from survivors.^[7] Wohlauer's 2157-patient trauma series adds the canary: day-2 AKI in just 2.13% carried 78% MOF incidence and 27% mortality, outperforming early cardiac, pulmonary or hepatic failure as a predictor of MOF and death.^[14] Buchman supplies the unifying frame — MODS terminology replacing MOF, three hypotheses (gut, molecular mediators, microvasculature) in one paradigm — and Vincent the admission fractions: sepsis in some 40% of ICU admissions, severe sepsis in 30%, shock in 15%, with deaths still rising because incidence outruns falling case-fatality.^[3][4] Border's 1992 Annals of Surgery paper carried the classic multiple-systems-organ-failure label into surgical teaching.^[6]

Sepsis-3 Framing — definitions, criteria, shock

Sepsis-3 defines sepsis as life-threatening organ dysfunction from a dysregulated host response, operationalised as a SOFA rise of 2 or more points marking greater than 10% in-hospital mortality, and septic shock as the vasopressor-dependent, lactate-above-2 subset with mortality above 40% — with qSOFA (respiratory rate 22 or more, altered mentation, systolic pressure 100 or less) as the non-ICU prompt at 2 or more points.^[29] Seymour's derivation and validation across 1.3 million encounters plus 706,399 confirmatory encounters proved the instrument split: in ICU, SOFA (AUROC 0.74) beat SIRS (0.64) and qSOFA (0.66); outside ICU, qSOFA (0.81) beat SOFA (0.79) and SIRS (0.76), with qSOFA of 2 or more multiplying mortality 3- to 14-fold across risk deciles.^[43] Raith's 184,875-patient ANZICS validation confirmed it in the critically ill: SOFA rise of 2 or more in 90.1% of infected admissions, AUROC 0.753 against 0.589 for SIRS and 0.607 for qSOFA — SIRS and qSOFA have limited mortality utility once the patient is already in ICU.^[46] Shock's own definition rests on Shankar-Hari's three-database exercise: systematic-review crude mortality 46.5%, with the vasopressor-to-MAP-65-plus-lactate-above-2 group dying at 42.3% — the examined shock criteria, not hypotension alone.^[44] And Rhee warns against quoting claims: across 409 US hospitals in 2014, clinical-criteria sepsis hit 6.0% of admissions with incidence flat from 2009-2014 (+0.6%/yr) while claims incidence rose 10.3%/yr — clinical criteria found sepsis with 69.7% sensitivity against claims' 32.3% at equal predictive value, so the examiner trusts electrons, not codes.^[45]

Endothelium & Microcirculation — immunothrombosis

Maneta's mechanism runs innate immunity into clot: neutrophils and monocytes trigger the coagulation cascade chiefly in the microcirculation — immunothrombosis — which walls off pathogen spread yet, through endothelial dysfunction and microthrombi, rapidly becomes multiorgan dysfunction; proposed rescues include cell-specific immune modulation and platelet-endothelial or platelet-activation blockade.^[38] Lelubre and Vincent set the bedside boundary: six systems are assessable and monitorable — cardiovascular including the microcirculation, respiratory, renal, neurological, haematological, hepatic — while the gut stays inaccessible, and bedside microcirculation visualisation remains a research tool despite two decades of sepsis-pathophysiology gains in inflammatory regulation, immunosuppression, mitochondrial and cell-death mechanisms.^[11] The same endothelial injury threads through AKI's distant-organ damage — leukocyte activation and infiltration, soluble cytokines and chemokines, endothelial injury, reactive oxygen species and dysregulated distant cell death across lung, heart, brain and liver.^[13]

Mitochondrial, Cardiac, Hepatic & Brain Injury — SIMD, SAE, SALI

Sepsis-induced myocardial dysfunction is intrinsic systolic-diastolic failure with worse outcomes, built from mitochondrial dysfunction, immune imbalance, metabolic reprogramming, excess reactive oxygen species and disordered calcium handling — with mitophagy protective, especially in survivors.^[40] Sepsis-associated encephalopathy spans mild confusion and delirium to deep coma via excessive microglial activation, endothelial barrier failure, tight-junction downregulation and leukocyte recruitment under systemic endotoxaemia and cytokines — microglial, endothelial and barrier-permeability modulation the therapeutic targets.^[39] Sepsis-associated liver injury moves in two phases — hyper-inflammatory then immunosuppressive — presenting usually as septic cholestasis with raised bilirubin but only mild transaminase shifts that conventional tests detect too late, while the gut-liver axis (dysbiosis, permeability, portal lipopolysaccharide, lost indole-3-propionic acid) drives injury and vasopressor dependence; management stays supportive — infection control plus organ support — with immunomodulation, metabolic/mitochondrial agents and microbiota restoration investigational.^[41] Kidney-brain crosstalk completes the circuit: acute injury couples the organs through cytokine amplification, leukocyte extravasation, oxidative stress and sodium/potassium/water channel dysregulation, and even dialysis and transplantation merely trade uraemic neurology for dialysis-era CNS complications.^[15]

Gut Origin, Dysbiosis & IAH/ACS — the surgical abdomen

The gut is the origin of systemic inflammation and the engine of multiple organ distress, with gut lymph pivotal in initiating ischaemia-reperfusion ARDS — the Gut Lymph theory of sepsis-to-MODS supported across the mesh of gut-lymph/lung-injury literature.^[42] Chen's MODS synthesis defines the syndrome as dysfunction of two or more organs during infection, shock or trauma, and places disrupted enteric composition and function at its centre — microbial products able to promote or to alleviate sepsis, making microbiota a therapeutic target rather than a bystander.^[54] The two crosstalk reviews make it actionable: gut-liver injury runs through dysbiosis, barrier loss, bacterial translocation and systemic inflammation (Sun), while the gut-kidney axis runs through diversity loss, pathobiont expansion, lipopolysaccharide translocation, TLR4/NF-kB tubular injury and fibrotic uremic toxins — indoxyl sulfate, p-cresol sulfate, TMAO — with renal failure feeding back to worsen gut homeostasis in a pathological loop that faecal transplant, probiotics or short-chain fatty acids might one day break.^[52][53] At the surgical bedside, De Waele names intra-abdominal hypertension an important contributor to organ dysfunction in surgical and medical critical illness alike, with kidney injury the watched outcome and IAP measurement, judicious fluids and decompressive laparotomy the contemporary management triad.^[49] The WSES open-abdomen guideline draws the vicious circle: damage-control resuscitation begets IAH/ACS, which begets deranged physiology and multiorgan failure unless abdominal decompression interrupts it — open only when no better option exists, close fascia-to-fascia as soon as physiology tolerates, and guard every step against the open abdomen's own harms.^[50] Bjorck extends the watch beyond trauma: ruptured AAA, pancreatitis, burns — incidence and mortality high, IAP measurement mandatory in any surgical patient with risk factors.^[51]

Kidney-Centred Crosstalk — AKI as cause and consequence

AKI strikes about half of critically ill patients and drags high in-hospital death, raised post-discharge death and CKD progression behind it — distant-organ injury via inflammatory cytokines, oxidative stress and immune responses now reframed as a systemic organ network balancing homeostasis, not a kidney plus one victim.^[9] Mayerhofer's 2025 review maps all five conversations: ARDS interplay through inflammation, haemodynamics and the ventilator itself; cardiorenal syndromes through venous congestion, immune response and RAAS dysregulation; liver, gut-barrier and brain injury all rooted in systemic IL-6/TNF-alpha inflammation activating endothelium and immunity across systems — with novel biomarkers and interventions still exploratory.^[10] Ricci's bidirectionality is the ventilator-round answer: AKI promotes lung injury even without positive fluid balance, while lung injury's hypoxaemia, hypercapnia and mechanical ventilation worsen renal haemodynamics and function — so optimise fluids, prevent inflammation and prevent lung stretch, with extracorporeal CO2 removal plus renal replacement on ECMO as the future pulmonary-renal option.^[12] Shiao inventories the long tail experimentally and clinically — liver, heart, brain, lung, gut, bone, immunity, even malignancy after temporary dialysis — through four mechanisms (acute uraemia, renal inflammation, disease modulation, the healthcare dilemma) and four pathways (cytokines/chemokines, leukocyte extravasation, oxidative stress, channel dysregulation).^[16]

Coagulation as Crosstalk — SIC before overt DIC

Iba's framing makes inflammation and coagulation the two joint drivers of septic organ dysfunction, with the ISTH's 2017 sepsis-induced coagulopathy score — platelets, prothrombin time, organ score — pragmatically catching early sepsis-associated DIC, and a two-step SIC-then-overt-DIC strategy grading severity where overt DIC alone arrives uncompensated and late.^[17] The precedence data justify the extra score: 98.7% of overt-DIC patients were already SIC-positive at baseline, 93.9% of day-2-to-4 overt DIC had prior SIC, and baseline SIC predicted death with 86.8% sensitivity against overt DIC's 64.5% — at the cost of lower specificity at every time point.^[18] Gando's 1438-patient multicentre validation then brakes enthusiasm: SIC and JAAM DIC diagnosed nearly all ISTH-DIC patients identically (94% and 98% on day 1), predicted day-4 ISTH DIC and MODS equally (AUCs 0.752 vs 0.740 and 0.697 vs 0.686), progressed identically (30.1% vs 28.6%) and survived identically — SIC adds little to current DIC scoring.^[19] Umemura's targeting rule governs therapy: Japanese meta-analysis plus nationwide data showed anticoagulants improving mortality only in DIC and never in non-DIC — host-protective local thrombosis must not be dissolved early — with recombinant-thrombomodulin benefit confined to high-severity DIC; unselected anticoagulation buys bleeding without survival.^[20] The ISTH's 2024-25 global survey of 153 clinicians in 27 countries explains why the rule matters: bleeding, petechiae and shock recognised, platelets/PT/fibrinogen/D-dimer commonly measured — yet only 28% used any formal DIC score despite 76% knowing the ISTH definition, with diagnostic uncertainty, heterogeneous presentation and resource limits (testing, transfusion, critical care) the named barriers.^[21]

SOFA Trajectories & Timing — delta beats admission

Vincent's 1449-patient, 40-ICU study is the trajectory anchor: median stay 5 days, 22% ICU mortality, infection on admission in 28.7% raising every organ score — and among 544 week-long stayers, total SOFA rose in 44% of nonsurvivors versus 20% of survivors while falling in 33% of survivors versus 21% of nonsurvivors, proving repeated scoring monitors disease development rather than merely labelling it.^[27] Cook's 1200-patient Canadian cohort times each organ: across baseline and serial MODS, cardiovascular, respiratory, renal and CNS components independently predicted ICU death (baseline RRs 1.5, 1.4, 1.3, 1.6; serial 1.4, 1.4, 1.5, 1.7) — but baseline and serial respiratory signals waited until week 2 and serial hepatic until week 4, so patterns vary by system and daily scores add value over admission scores throughout.^[34] Marshall's delta says the same from the development set: dysfunction acquired during the ICU stay — potentially manipulable dysfunction — out-explained admission severity in the mortality model.^[33] Frink offers the snapshot alternative with its limits stated: in 143 major-trauma patients, IL-6 predicted Marshall MODS at 84.7% accuracy but only 16.7% sensitivity (98.3% specificity), thresholds 761.7 pg/ml for MODS and 2176.0 pg/ml for death — a rule-in test, never a rule-out.^[36]

Resuscitation Endpoints at MOD Level — ANDROMEDA and EGDT

ANDROMEDA-SHOCK randomised 424 septic-shock patients across 28 ICUs to 8 hours of capillary-refill-targeted versus lactate-targeted resuscitation: 28-day death 34.9% versus 43.4% (hazard ratio 0.75, p=.06 — not significant) with 72-hour SOFA a point lower on perfusion targeting (5.6 versus 6.6, p=.045) and no other secondary moving — a mortality null containing an organ-dysfunction signal, with no protocol-related serious harm.^[28] The EGDT literature splits by comparator and context: Lu's 13-trial, 5268-patient meta-analysis with trial-sequential analysis found EGDT beating usual care (RR 0.87, moderate GRADE) yet losing to lactate-clearance-guided therapy (RR 1.60, low GRADE), with more fluids, transfusion, vasopressors and dobutamine in the first 6 hours as the likely mechanism.^[55] Simpson's living review agrees with the brake applied: overall EGDT-versus-usual-care null (RR 0.85) with substantial heterogeneity, no severity gradient, benefit confined to control mortality above 35%, and EGDT mortality higher than lactate-clearance/CVP monitoring — viable where mortality is high and 3-hour goals unmet, unnecessary where they are already met.^[56] The fence is examined: pressor choice, MAP targets and lactate management detail live in shock-surgical, bundle compliance in postoperative-sepsis — this topic is examined only on MOD-level endpoints, which is why Rivers, ProCESS, ARISE, ProMISe, CLASSIC and ARDSNet appear here solely through these two syntheses.^[55][56]

Support Sequencing — steroids help; bicarbonate, vitamin C, acetaminophen do not

APROCCHSS is the positive outlier: 1241 septic-shock patients, hydrocortisone-plus-fludrocortisone versus placebo, 90-day death 43.0% versus 49.1% (relative risk 0.88), ICU-discharge, hospital-discharge and day-180 mortality all lower, vasopressor-free days 17 versus 15 and organ-failure-free days 14 versus 12 — hyperglycaemia the price, serious adverse events otherwise equal.^[23] BICARICU-2 is the honest null: 640 severe-acidaemia-plus-AKI patients in 43 French ICUs, bicarbonate to pH 7.30 or nothing, day-90 death 62.1% versus 61.7% with day-28 and day-180 likewise flat — among 18 secondaries only kidney replacement moved (35% versus 50%), so bicarbonate spares KRT without saving lives.^[22] LOVIT is the harm signal: 872 vasopressor-dependent septic adults, 50 mg/kg vitamin C 6-hourly to 96 hours versus placebo, death-or-persistent-dysfunction at day 28 in 44.5% versus 38.5% (risk ratio 1.21) — more death (35.4% versus 31.6%) and more persistent dysfunction (9.1% versus 6.9%), with a severe hypoglycaemic and an anaphylaxis event on vitamin C.^[24] ASTER is the safe null with signals: 447 septic adults with respiratory or circulatory failure, 1 g IV acetaminophen 6-hourly for 5 days, organ-support-free days 20.2 versus 19.6 (p=.56) with liver enzymes, hypotension and fluid balance equal — yet total, respiratory and coagulation SOFA lower on days 2-4 and 7-day ARDS 2.2% versus 8.5%, cell-free-haemoglobin interaction absent.^[25] Patel adds the implementation verdict from 406 elective and emergency operations across 14 trusts: not one patient received full lung-protective ventilation — median tidal volume 8.4 ml/kg predicted weight, PEEP 4 with 152 patients given none — perioperative lung protection failing on adoption, not evidence.^[8]

Biomarkers — PCT diagnosis, prognosis and stewardship

For diagnosing sepsis, Tan's meta-analysis gives procalcitonin moderate value ahead of CRP: PCT SROC area 0.85 with sensitivity 0.80, specificity 0.77 and diagnostic odds 12.50, against CRP's 0.73, 0.80/0.61 and 6.89 — PCT the more accurate and specific of the pair.^[57] For prognosis, Liu's 23-study, 3994-patient meta-analysis makes elevation and especially non-clearance the signals: elevated PCT relative risk of death 2.60 (SROC 0.77), non-clearance RR 3.05 (SROC 0.79) — initial values of limited value, non-clearance the bedside risk test, optimal cutoffs still undefined.^[58] For stewardship, Schuetz's individual-patient Cochrane meta-analysis (26 trials, 6708 respiratory-infection patients) proves safety with benefit: PCT-guided initiation and stopping cut death (8.6% versus 10.0%, adjusted OR 0.83) and treatment failure trended down, while antibiotic exposure fell 2.4 days and side effects fell (adjusted OR 0.68) with stays unchanged.^[59] Rafiq's 2026 rapid review extends the verdict into ICU sepsis: PCT-guided stopping across 19 trials and 6382 patients saved 2.0 days with a 5% mortality-risk reduction (RR 0.95) at moderate certainty — CRP-guided stopping still unclear at very-low-to-low certainty.^[60] The 2025 mortality-prediction meta-analysis keeps the hierarchy honest across 29 studies and 41,469 patients: SOFA supreme (AUROC 0.819, sensitivity 0.77, specificity 0.73), clearly ahead of PCT, lactate and qSOFA — with lactate-adjusted qSOFA (0.823) matching SOFA by marrying bedside speed to lactate, high specificity suiting rapid risk exclusion in emergency and low-resource settings.^[48] Qiu's 57-study comparison completes the instrument panel: SIRS sensitive (0.85) but nonspecific (0.41), qSOFA specific (0.98) but insensitive (0.42), NEWS balanced (0.71/0.85) for diagnosis — while SOFA owns in-hospital mortality prediction (0.89/0.69).^[47]

Post-ICU Mortality & Function — the long tail

Inghammar's Swedish nationwide cohort (20,313 severe community sepsis versus 396,976 matched controls) measures the tail precisely: 56% of sepsis patients dead against 26% of controls, hazard 3.0 at 2-12 months, 1.8-1.9 at 1-5 years, still 1.6 beyond 5 years — infection, cancer and cardiovascular deaths leading, hazards largest in the previously healthy, readmissions tracking the same causes.^[61] Flick's CLOVERS-derived subtypes predict who: 1368 day-28 survivors sorted at discharge into five subtypes died at 13.1% by 3 months overall but 5.1% to 45.5% across subtypes — low-functional-status odds 11.1 and unhealthy-baseline odds 9.7 against low-risk — with subtype also predicting 6- and 12-month quality of life and daily-living limits, though not readmission.^[62] Yende's 483-patient, 12-hospital immune-trajectory study explains the biology: hyperinflammation-plus-immunosuppression (high hs-CRP plus sPD-L1) persisted in 68.3% at one year against 30.0% normal, carrying 1-year mortality odds 8.26 plus excess cardiovascular and cancer readmission-or-death — adjusted for demographics, comorbidity, severity, support and site.^[63] Ranzani's starting-point commentary keeps the examiner honest: Cuthbertson's 61% 5-year death after severe sepsis starts counting at ICU admission, and ICU-admission, ICU-discharge and hospital-discharge starting points describe different populations — standardise the start before comparing the tail.^[69]

PICS Recognition & Follow-up — screen the survivors

Post-intensive care syndrome is new or worsening physical, cognitive and/or mental impairment persisting after ICU — with long-term fatigue, pain and unemployment newly recognised alongside co-occurrence patterns, phenotypes, risk factors and mechanisms.^[64] Voiriot's pathophysiology review insists on permanence: ICU-acquired weakness with anabolic resistance and mitochondrial failure, delirium-linked cognitive injury on low-grade inflammation, lasting innate and adaptive immune alteration, acute-to-chronic kidney progression, post-ARDS pulmonary scarring — survivors disabled, resources consumed, suffering prolonged.^[65] J-PICS counts it: among ventilated Japanese survivors at 6 months, 63.5% carried at least one impairment and 17.8% two or more — physical 32.3%, cognitive 37.5%, mental 14.6% — with mandatory-education-only background quadrupling odds.^[66][66] The SCCM consensus converts recognition into orders: no existing tool reliably predicts PICS, so screen the high-risk — frail, already impaired, delirious, septic, ARDS, early anxiety/depression/PTSD — serially from 2-4 weeks after discharge with MoCA, HADS, IES-Revised, 6-minute walk and EQ-5D-5L, reconciled against pre-ICU function.^[67] Transitional care, Op't Hoog's five-trial review warns, has no proven PICS benefit yet — no significant physical or psychological gains, one nurse-led programme's 3-month physical signal excepted, paucity of research rather than proof of futility.^[68]

Exam Synthesis & Fence Map — what MOD owns

This topic owns four things and fences everything else: SOFA/Marshall/Denver trajectories and comparisons; organ-crosstalk framing (kidney-lung, kidney-brain, gut-liver, gut-lung, gut-kidney, cardiac, endothelial); multi-organ support sequencing with support-trial endpoints (SOFA-free and organ-support-free days); and post-ICU outcomes (mortality tails, PICS, function).^{[26][10][23][61]} Pressor choice, MAP targets and lactate resuscitation belong to shock-surgical; source control and hour-1/3-h bundles to postoperative-sepsis; tidal volumes, PEEP, prone and NMBAs to ards-surgical; KDIGO and RRT timing to acute-kidney-injury-surgical; ISTH/JAAM criteria detail to disseminated-intravascular-coagulation; IAH grades, pressures and decompression detail to abdominal-compartment-syndrome; feeding and GI-intolerance management to icu-nutrition-surgical; transfusion thresholds to massive-transfusion and damage-control-resuscitation.^{[28][50][8][19][21]} The one-paragraph MOD story for the viva: dysregulated host response injures endothelium, mitochondria and barriers; kidney, gut, lung, liver, heart and brain then injure each other through cytokines, leukocytes, oxidative stress and channel failure; scores track it and deltas predict it better than admission snapshots; hydrocortisone-plus-fludrocortisone helps septic shock while bicarbonate, vitamin C and acetaminophen do not move MOD endpoints; two-thirds of survivors stay inflamed-immunosuppressed and need structured screening.^{[37][16][34][23][63]} The three examined controversies each carry their brake: EGDT helps only above 35% control mortality (below that, lactate clearance wins); PCT stewardship safely stops antibiotics but does not diagnose sepsis alone; SOFA-2 modernises thresholds yet still excludes gut and immune dysfunction.^[56][60][26]

Exam Pearls — the one-liners that score

• SOFA-2 re-thresholds six systems over 3.34 million encounters (AUROC 0.79) but still excludes gut and immune — Marshall 24-point deltas out-explain admission scores.^[26][33]
• Denver labels fewest (22.8%) but predicts trauma death best (HR 3.87, specificity 81%); SOFA labels most (58.5%) with sensitivity 73%.^[2]
• A quarter of 351,942 polytrauma patients developed MOF across 40 definitions with no fall over time — definition moves incidence.^[1]
• Day-2 AKI (2.13%) predicts MOF (78%) and death (27%) better than early heart, lung or liver failure — the canary.^[14]
• Sepsis is SOFA rise of 2+ (>10% death); shock is vasopressors plus lactate above 2 (>40% death); qSOFA belongs outside ICU.^[29][43]
• SIC precedes overt DIC (98.7% already positive; mortality sensitivity 86.8 vs 64.5) yet equals JAAM DIC — score early, expect no extra.^[18][19]
• Anticoagulate only DIC, and thrombomodulin only high-severity DIC — unselected therapy bleeds without benefit; only 28% of clinicians score formally.^[20][21]
• Steroids cut shock death (43.0 vs 49.1%, RR 0.88, +2 organ-free days); bicarbonate (null, less KRT), vitamin C (harm, RR 1.21), acetaminophen (safe null) do not.^{[23][22][24][25]}
• ANDROMEDA: perfusion targeting did not cut death (34.9 vs 43.4%, p=.06) but lowered 72-hour SOFA — mortality null, organ signal.^[28]
• Gut lymph starts ARDS; dysbiosis-TLR4 injures kidney and liver; IAH/ACS demands IAP measurement and timely decompression with early fascial closure.^[42][53][50]
• PCT diagnoses modestly (SROC 0.85 beats CRP), non-clearance prognoses (RR 3.05), guidance stops antibiotics 2 days early without added death.^[57][58][59]
• Survivors die late (HR 3.0 at 2-12 months, 1.6 beyond 5 years); two-thirds stay inflamed-immunosuppressed (1-year death odds 8.26); subtypes at discharge predict it.^[61][63][62]
• PICS hits 63.5% at 6 months — screen the high-risk from 2-4 weeks with MoCA/HADS/IES-R/walk/EQ-5D; transitional care unproven.^[66][67][68]

Revision summary

Multiorgan dysfunction in surgical patients is scored by SOFA-2, Marshall (24 points, delta beats admission) and Denver (simplest, best early-trauma death signal at HR 3.87), with a quarter of polytrauma patients affected across 40 competing definitions. Sepsis-3 frames it (SOFA +2, shock as pressors-plus-lactate), endothelium and mitochondria mediate it, and kidney, gut, lung, liver, heart and brain injure each other — early AKI the canary, gut lymph the ARDS engine, SIC the early coagulation flag. Support sequencing favours only hydrocortisone-plus-fludrocortisone in shock (RR 0.88); bicarbonate, vitamin C (harm) and acetaminophen miss MOD endpoints; perfusion-targeted resuscitation misses mortality but trims SOFA. PCT guides stopping, not starting; survivors face tripled early hazard, persistent inflammation and PICS in nearly two-thirds — screen from 2-4 weeks.^{[26][1][29][14][42][18][23][28][60][61][66]}

A surgical patient has three missing SOFA components on day 3 (PaO2/FiO2, CVP, bilirubin the least available) — quote Braasch calculability (SOFA ~21%, MODS ~6%, Denver ~32%) and state the examined imputation warning.^[21]

life-threatening organ dysfunction from dysregulated host response; SOFA rise of 2+ marking >10% mortality; shock as vasopressor-dependent MAP 65+ with lactate >2 mmol/L and >40% mortality.^[44]

References69ShowHide

1. [1]Ting RS, et al. Incidence of multiple organ failure in adult polytrauma patients: A systematic review and meta-analysis. J Trauma Acute Care Surg, 2023.PMID 36809374
2. [2]Hutchings L, et al. Defining multiple organ failure after major trauma: A comparison of the Denver, Sequential Organ Failure Assessment, and Marshall scoring systems. J Trauma Acute Care Surg, 2017.PMID 28030507
3. [3]Buchman TG. Multiple organ failure. Curr Opin Gen Surg, 1993.PMID 7583986
4. [4]Vincent JL, et al. Classification, incidence, and outcomes of sepsis and multiple organ failure. Contrib Nephrol, 2007.PMID 17464116
5. [5]Barie PS, et al. Epidemiology of multiple organ dysfunction syndrome in critical surgical illness. Surg Infect (Larchmt), 2000.PMID 12594888
6. [6]Border JR. Multiple systems organ failure. Ann Surg, 1992.PMID 1503515
7. [7]Maziak DE, et al. The impact of multiple organ dysfunction on mortality following ruptured abdominal aortic aneurysm repair. Ann Vasc Surg, 1998.PMID 9514224
8. [8]Patel JM, et al. Intra-operative adherence to lung-protective ventilation: a prospective observational study. Perioper Med (Lond), 2016.PMID 27123237
9. [9]Matsuura R, et al. Acute kidney injury and distant organ dysfunction-network system analysis. Kidney Int, 2023.PMID 37030663
10. [10]Mayerhöfer T, et al. Kidney-organ interactions: recent advances and clinical implications. Curr Opin Crit Care, 2025.PMID 41165280
11. [11]Lelubre C, et al. Mechanisms and treatment of organ failure in sepsis. Nat Rev Nephrol, 2018.PMID 29691495
12. [12]Ricci Z, et al. Pulmonary/renal interaction. Curr Opin Crit Care, 2010.PMID 19935063
13. [13]Lee SA, et al. Distant Organ Dysfunction in Acute Kidney Injury: A Review. Am J Kidney Dis, 2018.PMID 29866457
14. [14]Wohlauer MV, et al. Acute kidney injury and posttrauma multiple organ failure: the canary in the coal mine. J Trauma Acute Care Surg, 2012.PMID 22327979
15. [15]Lu R, et al. Kidney-brain crosstalk in the acute and chronic setting. Nat Rev Nephrol, 2015.PMID 26281892
16. [16]Shiao CC, et al. Long-term remote organ consequences following acute kidney injury. Crit Care, 2015.PMID 26707802
17. [17]Iba T, et al. Roles of Coagulation Abnormalities and Microthrombosis in Sepsis: Pathophysiology, Diagnosis, and Treatment. Arch Med Res, 2021.PMID 34344558
18. [18]Iba T, et al. Newly Proposed Sepsis-Induced Coagulopathy Precedes International Society on Thrombosis and Haemostasis Overt-Disseminated Intravascular Coagulation and Predicts High Mortality. J Intensive Care Med, 2020.PMID 29720054
19. [19]Gando S, et al. Utility of Sepsis-induced Coagulopathy Among Disseminated Intravascular Coagulation Diagnostic Criteria: A Multicenter Retrospective Validation Study. Thromb Haemost, 2025.PMID 39900104
20. [20]Umemura Y, et al. Optimal patient selection for anticoagulant therapy in sepsis: an evidence-based proposal from Japan. J Thromb Haemost, 2018.PMID 29316171
21. [21]Nwagha TU, et al. Global practice and challenges in the diagnosis and management of disseminated intravascular coagulation: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation. J Thromb Haemost, 2026.PMID 41655787
22. [22]Jung B, et al. Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury: The BICARICU-2 Randomized Clinical Trial. JAMA, 2025.PMID 41159812
23. [23]Annane D, et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med, 2018.PMID 29490185
24. [24]Lamontagne F, et al. Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit. N Engl J Med, 2022.PMID 35704292
25. [25]Ware LB, et al. Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis: The ASTER Randomized Clinical Trial. JAMA, 2024.PMID 38762798
26. [26]Ranzani OT, et al. Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score. JAMA, 2025.PMID 41159833
27. [27]Vincent JL, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on 'sepsis-related problems' of the European Society of Intensive Care Medicine. Crit Care Med, 1998.PMID 9824069
28. [28]Hernández G, et al. Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial. JAMA, 2019.PMID 30772908
29. [29]Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016.PMID 26903338
30. [30]Vincent JL, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med, 1996.PMID 8844239
31. [31]Moreno R, et al. The Sequential Organ Failure Assessment (SOFA) Score: has the time come for an update?. Crit Care, 2023.PMID 36639780
32. [32]Vincent JL. Organ dysfunction in patients with severe sepsis. Surg Infect (Larchmt), 2006.PMID 16895511
33. [33]Marshall JC, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med, 1995.PMID 7587228
34. [34]Cook R, et al. Multiple organ dysfunction: baseline and serial component scores. Crit Care Med, 2001.PMID 11700393
35. [35]Braasch MC, et al. Availability of Multiple Organ Failure Score Components in Surgical Patients. Surg Infect (Larchmt), 2022.PMID 35076318
36. [36]Frink M, et al. IL-6 predicts organ dysfunction and mortality in patients with multiple injuries. Scand J Trauma Resusc Emerg Med, 2009.PMID 19781105
37. [37]Arina P, et al. Pathophysiology of sepsis. Curr Opin Anaesthesiol, 2021.PMID 33652454
38. [38]Maneta E, et al. Endothelial dysfunction and immunothrombosis in sepsis. Front Immunol, 2023.PMID 37081895
39. [39]Gao Q, et al. Sepsis-Associated Encephalopathy and Blood-Brain Barrier Dysfunction. Inflammation, 2021.PMID 34291398
40. [40]Yang H, et al. Sepsis-induced myocardial dysfunction: the role of mitochondrial dysfunction. Inflamm Res, 2021.PMID 33683374
41. [41]Geladari EV, et al. Sepsis and the Liver. Diseases, 2025.PMID 41439929
42. [42]Jin C, et al. Gut-lymph-lung pathway mediates sepsis-induced acute lung injury. Chin Med J (Engl), 2020.PMID 32858588
43. [43]Seymour CW, et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016.PMID 26903335
44. [44]Shankar-Hari M, et al. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016.PMID 26903336
45. [45]Rhee C, et al. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014. JAMA, 2017.PMID 28903154
46. [46]Raith EP, et al. Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit. JAMA, 2017.PMID 28114553
47. [47]Qiu X, et al. SIRS, SOFA, qSOFA, and NEWS in the diagnosis of sepsis and prediction of adverse outcomes: a systematic review and meta-analysis. Expert Rev Anti Infect Ther, 2023.PMID 37450490
48. [48]Lu J, et al. Predictive value of SOFA, PCT, Lactate, qSOFA and their combinations for mortality in patients with sepsis: A systematic review and meta-analysis. PLoS One, 2025.PMID 40961067
49. [49]De Waele JJ. Intra-abdominal hypertension and abdominal compartment syndrome. Curr Opin Crit Care, 2022.PMID 36194128
50. [50]Coccolini F, et al. The open abdomen in trauma and non-trauma patients: WSES guidelines. World J Emerg Surg, 2018.PMID 29434652
51. [51]Björck M, et al. Intra-abdominal hypertension and abdominal compartment syndrome in nontrauma surgical patients. Am Surg, 2011.PMID 21944455
52. [52]Sun J, et al. Gut-liver crosstalk in sepsis-induced liver injury. Crit Care, 2020.PMID 33076940
53. [53]Zhang H, et al. Gut microbiota and sepsis-associated acute kidney injury: a narrative review. Front Immunol, 2026.PMID 42311675
54. [54]Chen P, et al. Gut Microbiota and Multiple Organ Dysfunction Syndrome (MODS). Adv Exp Med Biol, 2020.PMID 32323186
55. [55]Lu Y, et al. Early Goal-Directed Therapy in Severe Sepsis and Septic Shock: A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. J Intensive Care Med, 2018.PMID 27756870
56. [56]Simpson SQ, et al. Early goal-directed therapy for severe sepsis and septic shock: A living systematic review. J Crit Care, 2016.PMID 27546746
57. [57]Tan M, et al. The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: A systematic review and meta-analysis. J Cell Biochem, 2019.PMID 30417415
58. [58]Liu D, et al. Prognostic Value of Procalcitonin in Adult Patients with Sepsis: A Systematic Review and Meta-Analysis. PLoS One, 2015.PMID 26076027
59. [59]Schuetz P, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev, 2017.PMID 29025194
60. [60]Rafiq S, et al. Clinical effectiveness of procalcitonin- or C-reactive protein-guided antibiotic discontinuation protocols for adult patients who are critically ill with sepsis: a rapid systematic review and meta-analysis. Anaesthesia, 2026.PMID 41505903
61. [61]Inghammar M, et al. Long-term Mortality and Hospital Readmissions Among Survivors of Sepsis in Sweden: A Population-Based Cohort Study. Open Forum Infect Dis, 2024.PMID 38962525
62. [62]Flick RJ, et al. Association of Sepsis Survivor Subtypes With Long-Term Mortality and Disability After Discharge: A Retrospective Cohort Study. Crit Care Med, 2026.PMID 41231072
63. [63]Yende S, et al. Long-term Host Immune Response Trajectories Among Hospitalized Patients With Sepsis. JAMA Netw Open, 2019.PMID 31390038
64. [64]Hiser SL, et al. Post-intensive care syndrome (PICS): recent updates. J Intensive Care, 2023.PMID 37221567
65. [65]Voiriot G, et al. Chronic critical illness and post-intensive care syndrome: from pathophysiology to clinical challenges. Ann Intensive Care, 2022.PMID 35779142
66. [66]Kawakami D, et al. Prevalence of post-intensive care syndrome among Japanese intensive care unit patients: a prospective, multicenter, observational J-PICS study. Crit Care, 2021.PMID 33593406
67. [67]Mikkelsen ME, et al. Society of Critical Care Medicine's International Consensus Conference on Prediction and Identification of Long-Term Impairments After Critical Illness. Crit Care Med, 2020.PMID 32947467
68. [68]Johanna Josepha Op't Hoog SA, et al. The effects of intensive care unit-initiated transitional care interventions on elements of post-intensive care syndrome: A systematic review and meta-analysis. Aust Crit Care, 2022.PMID 34120805
69. [69]Ranzani OT, et al. Long-term mortality after critical care: what is the starting point?. Crit Care, 2013.PMID 24073631